Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 16/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.66 |
| ▸ | HPGD | P15428 | 10/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 5/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 7/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8885364 | 0.90 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL2587537 | 0.88 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL8884786 | 0.83 | ALDH1A1 (0.76) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL23860992 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL2592629 | 0.79 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL18496678 | 0.79 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL15648490 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Hydrochloric Acid SCHEMBL18496649 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL17734330 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL15492822 | 0.76 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142504-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| US-4451469-A | Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics | STERLING DRUG INC. (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | KDM4E 2573/4885ALDH1A1 48/4885HPGD 257/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | KDM4E 711/4885ALDH1A1 358/4885HPGD 133/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1253/4885ALDH1A1 45/4885HPGD 403/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | KDM4E 753/4885ALDH1A1 324/4885HPGD 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.